How To Write An Effective Letter: FDA Advises Sponsors On Crafting Drug Alerts
This article was originally published in The Pink Sheet Daily
Executive Summary
Guidance on “Dear Doctor” letters says companies should evaluate the effectiveness of their communications – but solely for their own use.
You may also be interested in...
FDA’s “Dear Doc” Final Guidance Yields To One Industry Request, Denies Another
Agency offers a sneak peek into final “Dear Health Care Provider Letters” guidance, decreasing some of industry’s burden, while refusing to cave on other requirements.
Companies Reveal Hurdles In Providing Drugs Via Expanded Access Programs
GSK, Stealth BioTherapeutics and Blueprint Medicines discuss the difficulties getting participation of physicians, the excessive cost of expanded access, and whether physicians should report research data.
Current Pathways For Rare Disease Drugs Are Not Optimal, US FDA’s Califf Says
Anticipating a ‘tsunami of therapies’ for rare diseases, commissioner says the agency will have to think of creative approaches and employ regulatory flexibility for them. FDA considers copying the oncology center’s Project Facilitate for expanded access to other diseases.